Model
Edge
Pernix Therapeutics Holdings, Inc.
0001024126
Filing Type
10-Q
Filing Date
11/12/2018
Updated
11/9/18, 11:58 AM
Filing
10-Q
Earnings Release
Exhibits
10-Q
10-Q
EX-3.1
ARTICLES SUPPLEMENTARY FOR 0% SERIES C PERPETUAL CONVERTIBLE PREFERRED STOCK
EX-10.1
STOCKHOLDERS AGREEMENT, DATED JULY 27, 2018, BY AND AMONG NALPROPION PHARMACEUTICALS, INC.,
EX-10.2
SERVICES AGREEMENT, DATED JULY 27, 2018, BETWEEN NALPROPION PHARMACEUTICALS, INC. AND PERNIX THERAPEUTICS, LLC
EX-10.6
AMENDMENT NO. 3 TO THE ABL FACILITY, AUGUST 1, 2018, BY AND AMONG PERNIX, THE GUARANTORS AND LENDERS PARTY THERETO
EX-10.7
AMENDMENT NO. 2 TO THE TERM FACILITY, DATED AUGUST 1, 2018, BY AND AMONG PIP DAC, THE LENDERS PARTY THERETO
EX-10.8
FIRST SUPPLEMENTAL INDENTURE, DATED JULY 27, 2018, BETWEEN PERNIX THERAPEUTICS HOLDINGS, INC. AND WILMINGTON TRUST,
EX-31.1
CEO 302 CERTIFICATE
EX-31.2
CFO 302 CERTIFICATE
EX-32.1
906 CERTIFICATE
GRAPHIC
LOGO
EX-101.INS
XBRL INSTANCE DOCUMENT